Li Gong, Sijia Huang, Bingxin Dai, Pingping Wang, Hailan Qin, Fangting Wu, Gangqiang Xu, Siwei Xia, Weice Sun, Qingyue Hu, Zhenhua Zhang, Zhenzhong Feng, Cuiping Ren, Jijia Shen, Miao Liu
Hepatic fibrosis is driven by sustained activation of hepatic stellate cells (HSCs), but the post-transcriptional mechanisms that couple pathogen-induced liver injury to HSC activation remain poorly understood. Here, we profiled circular RNAs (circRNAs) in primary HSCs from Schistosoma japonicum-infected mice and identified circFgfr2, a 639-nt circRNA generated from exons 3-6 of Fgfr2, as a fibrosis-associated transcript. CircFgfr2 was reduced in activated HSCs and fibrotic mouse livers. In human liver specimens from mixed non-schistosomal etiologies, reduced circFgfr2 expression was associated with greater fibrosis severity. CircFgfr2 displayed canonical circular features, including a back-splice junction, resistance to RNase R and enhanced transcript stability, and was predominantly cytoplasmic. Mechanistically, the RNA-binding protein Fused in Sarcoma (FUS) promoted circFgfr2 biogenesis by binding the downstream flanking intron of pre-Fgfr2. CircFgfr2 overexpression suppressed HSC activation and proliferation, whereas selective circFgfr2 knockdown increased α-SMA and COL1A1 expression in JS-1 cells. In vivo, early adeno-associated virus serotype 8 (AAV8)-mediated circFgfr2 overexpression attenuated the subsequent development of schistosomiasis-associated hepatic fibrosis. In the murine experimental system, cytoplasmic circFgfr2 acted as a competing endogenous RNA (ceRNA) for mmu-miR-1941-5p, thereby relieving mmu-miR-1941-5p-mediated repression of dimethylarginine dimethylaminohydrolase 1 (DDAH1), reducing intracellular reactive oxygen species (ROS) accumulation, and altering autophagy-related signaling. These findings support an inhibitory role of circFgfr2 in HSC activation and experimental hepatic fibrogenesis and establish a circFgfr2/mmu-miR-1941-5p/DDAH1 regulatory pathway in the murine experimental system. However, the efficacy of circFgfr2 against established fibrosis and conservation of the murine miRNA-mediated mechanism in humans remain to be determined.